Onward’s Arc-Ex spinal cord stimulator earned the European Union’s CE Mark, according to a Sept. 8 news release.
The company expects to begin commercial sales of the Arc-Ex in the fourth quarter beginning in Germany. The spinal cord stimulator is designed to improve hand strength and sensation in adults with chronic, incomplete spinal cord injuries.
Clinical studies of the device show that 90% of participants improved strength or function, and 87% reported improved quality of life.
Onward’s Arc-Ex was FDA-approved in 2024. In the U.S., Onward began its phased launch in 2025.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
